Monday, November 1, 2021

T-Cell Immunotherapy stock $PDSB primed to run?

In evaluating PDS Biotechnology, noting immunotherapy is considered as perhaps having the greatest area of potential for developing effective cancer drugs utilizing our own immune system, I found the company description really attractive. 

Is T-Cell immunotherapy stock $PDSB primed to run?


 

No comments: